Kerala's Switch to Generic SMA Drug Raises Safety and Affordability Debate
Kerala's government replaced the branded SMA drug Evrysdi with a lower-cost generic version, Natsmart, sparking debate over safety and affordability. Parents and opposition leaders, including former health ministers, have raised concerns about the generic drug's quality and labels suggesting clinical trial use. The health minister defended the switch, citing safety and affordability, while public health experts support the generic option to expand access. The controversy highlights tensions between cost, treatment efficacy, and regulatory transparency in Kerala's SMA program.
First-hand measurement across 15 sources
We measured how 15 outlets covered this story. Coverage leans balanced overall (Left 4%, Centre 70%, Right 26%). Overall sentiment is neutral (54/100). Lens Score 71/100.
Outlets measured: thenewsminute, thehindu, news18, thehindu, news18, deccanherald, thehindu, news18, and 7 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 13 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment ranged widely across outlets — from 28/100 to 70/100 — a sign the coverage itself was contested, not just reported.
Coverage timeline
indiatoday broke this story on 21 Oct, 09:38 am. Other outlets followed.